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The porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most
important swine diseases in the world. It is causing an enormous economic burden due
to reproductive failure in sows and a complex respiratory syndrome in pigs of all ages,
with mortality varying from 2 to 100% in the most extreme cases of emergent highly
pathogenic strains. PRRSV displays complex interactions with the immune system and
a high mutation rate, making the development, and implementation of control strategies
a major challenge. In this review, the biology of the virus will be addressed focusing
on newly discovered functions of non-structural proteins and novel dissemination
mechanisms. Secondly, the role of different cell types and viral proteins will be reviewed
in natural and vaccine-induced immune response together with the role of different
immune evasion mechanisms focusing on those gaps of knowledge that are critical to
generate more efficacious vaccines. Finally, novel strategies for antigen discovery and
vaccine development will be discussed, in particular the use of exosomes (extracellular
vesicles of endocytic origin). As nanocarriers of lipids, proteins and nucleic acids,
exosomes have potential effects on cell activation, modulation of immune responses
and antigen presentation. Thus, representing a novel vaccination approach against this
devastating disease.
Keywords: porcine reproductive and respiratory syndrome virus, PRRSV, virus biology, immunology, vaccinology,
extracellular vesicles
ECONOMIC IMPACT
PRRSV is responsible for respiratory disease in weaned and growing pigs, as well as reproductive
failures in sows. It is considered one of the most important swine diseases worldwide, with an
economic impact estimated at $664 million in losses every year to U.S. producers, representing
an increase of 18.5% in the last 8 years (1, 2). In Europe, the situation is similar and economic
disease models have been carried out to determine the economic burden in the best and worst case
scenario combining reproductive failure and respiratory disease, estimating annual losses from a
median of e75,724, if the farm was slightly affected during nursing and fattening, to a median of
e650,090 if a farm of 1,000 sows is severely affected in all productive phases (3). Nevertheless, there
is scarce of information about the economic impact of this disease as a consequence of multiple
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factors (vaccination, treatment, respiratory symptoms,
reproductive failure, and other PRRSV-related diseases)
making a difficult task to quantify exactly this parameter under
field conditions. Thus, the exact economic impact of PRRSV
remains a key gap in the knowledge for this disease.
BIOLOGY OF PRRSV
The porcine reproductive and respiratory syndrome virus
(PRRSV) was first isolated in the early 1990s in Europe and
North America (4, 5). It is an enveloped single-stranded positive-
sense RNA virus of the family Arteriviridae,Genus Porarterivirus
according to the International Committee of Taxonomy of
Viruses (6). Presently, there are four distinct species included
in this Genus (Porarterivirus), PRRSV-1 and PRRSV-2 (with
30–45% variation in nucleotide sequences), along with other
two viruses that do not affect pigs (Lactate dehydrogenase-
elevating virus and Rat Arterivirus 1) (7). The genome size of
PRRSV is about 15 kb with 10 open reading frames (ORFs),
with replicase genes located at the 5′-end followed by the
genes encoding structural proteins toward the 3′-end (8). The
majority of the genome (∼60–70%) encodes non-structural
FIGURE 1 | Genome structure and mature viral particle of PRRSV virus. (A) Non-structural proteins are located in the 5′ end of the genome, codifying for two different
polyproteins pp1a and pp1ab that are cleaved into at least 14 nsps (nsp1 to nsp12 and nsp1α and nsp1β, and nsp7α, and nsp7β). Structural proteins located near
the 3′ end, are associated to the viral envelope and RNA packaging. (B) PRRSV mature viral particle, composed of a lipid bilayer envelop with viral receptor
glycoproteins involved on infection and cell internalization. Single stranded positive RNA is associated with nucleocapsid protein in the internal layer of the virus.
proteins involved in replication (ORF1a and ORF1ab), whereas
ORFs 2–7 encodes structural proteins (N, M, GP2-GP5, E)
(Figures 1A,B) (9). Using ORF5 in molecular epidemiological
studies, an enormous genetic variability has been described (10).
Yet, data on whole genome sequencing is scarce and constitute
another important gap in the knowledge of this virus and its
evolution (Box 1).
PRRSV replicase genes consist of two ORFs, ORF1a and
ORF1b, which occupy the 5′ proximal three-quarters of the
genome (Figure 1A). Both are expressed from the viral genome,
with expression of ORF1b depending on a conserved ribosomal
frameshifting mechanism. Subsequently, extensive proteolytic
processing of the resulting pp1a and pp1ab polyproteins yields
at least 14 functional non-structural proteins (nsps), specifically
nsp1 to nsp12, with both the nsp1 and nsp7 parts being subject
to internal cleavage (giving origin to nsp1α and nsp1β, and
nsp7α, and nsp7β, respectively), most of which assemble into
a membrane-associated replication and transcription complex
(11). Recently, a programmed ribosomal frameshift encoding
an alternative ORF that generates two extra proteins, nsp2TF
and nsp2N, was discovered in PRRSV and other Arteriviruses
(12, 13). These nsps, described for PRRSV, have proven to
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BOX 1 | Gaps in knowledge in PRRSV.
be necessary and sufficient for the induction of membrane
modifications resembling those found in infected cells (14). Most
importantly, all positive RNA viruses seem to induce one of two
basic morphotypes of membrane modifications: invaginations or
double-membrane vesicles.
PRRSV also has a set of 8 structural proteins, including a small
non-glycosylated protein and a set of glycosylated ones: GP2a-
b, GP3, GP4, GP5, and GP5a, M and N proteins (15). However,
nsp2, traditionally classified as a non-structural protein, has
been found to be incorporated in multiple isoforms within
the viral envelope (Ovarian tumor domain protease region,
hypervariable region and C-terminal region) (16), giving new
insights into the structure of this virus (Figure 1B). First, the
nucleocapsid protein (N), as one of the most important parts
of the mature viral particle, has been deeply characterized
on PRRSV, finding important features shared in most non-
segmented RNA viruses. The N protein consists of 123 amino
acids for genotype 2 and 128 amino acids for genotype 1.
The viral envelope glycoproteins (GP2 to GP5) are the first
interactors with host cell receptors to initiate infection and
are exposed to the immune system when viral particles are in
blood and lymphoid tissue circulation (Figure 2). There is also
another protein that contribute to virion structure, M protein,
that is required during viral entry to interact with heparan
sulfate cell receptor on macrophages. Later, GP5 is thought to
bind to sialoadhesin and virus internalization and uncoating is
triggered by a formation of a viral heterotrimer (GP2a, GP3,
and GP4) with scavenger receptor CD163 (Figure 2) (17, 18).
GP5 is the most abundant glycoprotein. First, it interacts with
two cell entrymediators, heparan sulfate glycosaminoglycans and
sialoadhesin/CD169 (17, 18) to favor viral entry and then possibly
with the N protein and its MHC-like domain to carry N-Viral
RNA complex to the budding site (Figure 2). GP2, GP3, and GP4
are protected with glycan shields, like most PRRSV membrane
proteins, to avoid antibody recognition and neutralization. GP2
has two glycosylation sites, GP3 have seven and GP4 have four,
Frontiers in Veterinary Science | www.frontiersin.org 3 February 2019 | Volume 6 | Article 38
Montaner-Tarbes et al. Key Gaps in the Knowledge of PRRSV
FIGURE 2 | Interactions between viral proteins and cell receptors for virus attachment, entry, uncoating and release of genetic ssRNA to cell cytoplasm. Blocking
CD163, CD151 tetraspanin or vimentin seems to inhibit viral replication or infection in the host cell, but reduced replication or no effect is seen when receptors such as
heparan-sulfate or siglec-1 are blocked, demonstrating that some viral proteins and cell receptors are indispensable in terms of production of infectious viral progeny
and dissemination in the host.
three of which are directly related to virus survival, causing lethal
damage in virus production when more than two of these sites
are mutated (19) (Figure 2).
VIRUS REPLICATION AND ENTRY
MECHANISMS IN HOST CELLS
Viral replication starts by interaction of viral glycoproteins with
different cellular receptors (Figure 2) (17). CD163 and CD169
play a main role during infection, uncoating of the viral particle,
activation of clathrin-mediated endocytosis and release of viral
genome in the cytoplasm (20). CD163 has been defined as
the main receptor for viral infection by evaluating the effect
of PRRSV on CD163 knockout pigs, where there is complete
resistance to infection (21). Cysteine-rich domain 5 in this
receptor seems to be necessary to establish interactions with
PRRSV-1 species, since its deletion by CRISPR/Cas9 system
(exon 7 of the gene encoding this region) implies protection
for a large panel of these viruses demonstrated by in vitro
challenge of edited-pig macrophages and in vivo experiments
with 1SRCR5 animals (22–24). More important, edited pigs
show no side effects when kept under standard husbandry
conditions and CD163 seems to maintain its biological
function (hemoglobin-haptoglobin scavenger) regardless the
lacking cysteine-rich 5 domain, nevertheless, other unknown
functions could be impaired by this modification. In conclusion,
gene-edited pigs lacking SRCR5 region of CD163 could be an
important asset to confront PRRSV epidemics with the final
goal of eradication.
CD169 seems to be related only to co-interactions with
sialic acid in the virion surface, however, knockout pigs for
either exon 1, 2, or 3 of CD169 were not protected from
infection and viral load as well as antibody responses were similar
to heterozygous (CD169+/−) or wild type pigs (CD169+/+)
(25). The former experiments suggested that other unknown
mechanisms could be involved in PRRSV infection such as other
receptors, new unknown susceptible cell types different from
macrophages or possible leaking of CD169 expression in the
knockout model.
Other molecules are also involved in viral entry, such as
CD151 (26) and vimentin (27); blocking of any of these four
molecules (CD163, CD169, CD151, and vimentin) had an
effect on viral infection, either on internalization or complete
inhibition of viral replication (17). After cell entry, PRRSV causes
a series of intracellular modifications to complete its replication
cycle, which includes rearrangements of intracellular membrane
organelles to generate the replication complex. These include the
formation of perinuclear double membrane vesicles apparently
derived from endoplasmic reticulum, synthesis of genomic
RNA (gRNA), transcription of segmented RNA (sgRNA) and
expression of viral proteins (20, 28). At late stages of replication,
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the mature virions accumulate in the intracellular membrane
compartments and they are then released into the extracellular
space through exocytosis (29).
A non-classical spread pathway has been detected in several
viruses including PRRSV where virus dissemination is mediated
by cell to cell nanotubules (30). It was reported that almost
all PRRSV proteins interact with myosin and actin (especially
F-actin and Myosin IIA) where nanotubules connected cells
allowing the movement of structural proteins and RNA, infecting
naïve cells in a non-classical way even in the presence of
neutralizing antibodies in the cell media. In addition, this
non-classical pathway demonstrated that PRRSV cell entry
receptors were not necessary to establish infection, as non-
permissive cells became infected when were contacted by
infected cells via nanotubes. This spreading strategy has been
proposed as a mechanism to facilitate infection either by
surfing of viral particles between adjacent cell membranes
or as a receptor-independent mechanism for infection (31);
Importantly, has been reported for other viruses such as HIV-
1 where nanotube number on macrophages increases after
infection (32) and Herpesvirus transmission between bovine
fibroblasts (33). Interestingly, although several viral proteins
were detected in nanotubules (nsp1β, nsp2, nsp2TF, nsp4,
nsp7, and nsp8, GP5 and N), GP4 was detected in only a
few nanotubes. In particular, the role of GP4 in this non-
classical spread pathway is not fully understood and it will be
interesting to further evaluate GP4 interaction with other cellular
components to elucidate the reason why GP4 is not transported
to new recipient naïve cells. Altogether these data indicate that
PRRSV has evolved different pathways to spread even though,
in vivo, the virus shows narrow cell tropism for monocytes and
macrophages (34, 35) (Box 1).
IMMUNOLOGY OF PRRSV AND
MECHANISMS INVOLVED IN IMMUNE
EVASION
Innate Immune Response
The innate immune response is the first system any given
pathogen encounters, specially to prevent viral replication and
invasion into mucosal tissues (respiratory tract in the case
of PRRSV) and, importantly, to initiate the strong adaptive
immune response to fight against intracellular infectious agents
(7). Type I interferons (IFN α/β) comprise one of the most
potent mechanisms against invading viruses in the first stages
of infection, triggering an array of IFN-stimulated genes (ISG)
(36). Generally speaking, all nucleated cells have the ability to
produce IFN α/β, but plasmacytoid DC (pDC) are the most
potent producers of this family of cytokines (37). PRRSV has
evolved a set of mechanisms for suppressing IFN α/β in vivo,
maintaining low expression levels of this cytokines on infected
pigs (38) during almost all time-course of infection shortly
after transient elevation in the lungs (39). Suppression of IFN
α/β also takes place in vitro in PRRSV infected MARC-145
and porcine alveolar macrophages (38, 40, 41). Further studies
have shown that IFN type I suppression is a major strategy
of PRRSV to modulate host antiviral defense. In fact, several
viral proteins have been identified as IFN antagonists (nsp1α,
nsp1β, nsp2, nsp4, nsp11, and N) (7, 42–44). As an example
for N protein, upon dsRNA stimulation, IFN-β production
was shown to decrease proportionally with increasing levels of
N expression and additionally it was found to downregulate
IFN-dependent gene production by dsRNA interfering with
dsRNA-induced phosphorylation and nuclear translocation of
IRF3 (45).
Among PRRSV non-structural proteins with type I IFN
modulation capacity, nsp1 has been considered as the strongest
antagonist of IFN-β production by acting on interferon
regulatory factor 3 (IRF3) phosphorylation and nuclear
translocation. Almost all nsps, excepting nsp1, have been
related to the perinuclear region, associated with intracellular
membranes, supposedly derived from the endoplasmic reticulum
(ER), which are modified into vesicular double-membrane
structures with which the viral replication and transcription
complex (RTC) is thought to be associated with (14, 46, 47).
Nsp1 translocates to the nucleus during the first hours of
infection, where it is capable of inhibiting IRF3 association
with CREB-binding protein (CBP), promoting CBP degradation
by a proteasome-dependent mechanism, without which the
transcription enhanceosome may not assemble the transcription
machinery for the interferon expression (15, 46). Recently,
post-transcription protein expression of IFN β was shown to be
regulated by PRRSV by means of upregulating cellular miRNA
in porcine alveolar macrophages (48)
Nsp2 is the largest (mature) PRRSV protein and contains at
least four distinct domains: The N-terminal CP/OTU domain, a
central hypervariable region, a putative transmembrane domain,
and a C-terminal region of unknown function that is rich in
conserved cysteine residues. This protein is unique in the context
of PRRSV due to its genetic heterogeneity, its participation
in diverse roles supporting the viral replication cycle, and its
packaging within the PRRSV virion (16, 49). Previous studies
suggest that nsp2 has different roles related to immune evasion
mechanisms. It has been determined that nsp2 OTU domain
(thiol-dependent deubiquitinating domain) inhibits the nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-kB) by
interfering with the polyubiquitination process of IkBα (nuclear
factor of kappa light polypeptide gene enhancer in B-cells
inhibitor) and, subsequently, preventing the degradation of the
IkBα protein (50). Moreover, viable deletion mutants in nsp2,
when infecting cells, caused a downregulation of cytokines (IL-
1β and TNF-α) mRNA expression, in comparison with that of
parental virus, suggesting that certain regions of nsp2 might
contribute to the induction of a virus-specific host immune
response and that deletion of such a region could produce a more
virulent virus (51).
There are several isoforms of nsp2, sharing a consistent
core set between viral strains, which are integrated into mature
virion at the final stage of replication (Figure 1B), although
some of them could be strain-specific. Inclusion of nsp2
within the PRRSV virion suggests that it may function in
previously unknown roles related to extracellular function, entry,
or immediate-early viral replication events (16). Truncated
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forms of nsp2 have also been identified, named nsp2TF and
nsp2N, with apparent roles in modulation of immune evasion.
When deletion mutants for those forms were used to infect
cells, there was a significant change in gene expression, a
strong activation of those involved in cytokine-cytokine receptor
interaction, TNF signaling, toll-like receptor signaling, NOD-
like receptor signaling, NF-κB signaling, RIG-I-like receptor
signaling, chemokine signaling, JAK-STAT signaling, cytosolic
DNA-sensing, and NK cell mediated cytotoxicity (13), suggesting
that an active role (direct or indirect) is played by these truncated
forms in modulating host cells innate immune response,
making PRRSV infectious cycle more complicated than it was
initially thought.
Nsp11, is a Nidovirus conserved endoribonuclease with
an uridylate-specific endonuclease (NendoU). It has been
demonstrated in vitro that overexpression of nsp11 enhanced
viral titter (52). Moreover, nsp11 antagonizes type I IFN,
specifically IFNβ production, activated by the retinoic acid
inducible gene 1 like receptor, showing substrate specificity
toward Mitochondrial Antiviral Signaling proteins (MAVS)
and RIG-I (transcripts and proteins), and demonstrating that
this activity was associated to the endoribonuclease activity
of this protein in which transfection mutant viruses were
unable to degrade MAVS mRNA and impair IFNβ production
(53). Another mechanism whereby this protein limits antiviral
response is related to inflammasome and synthesis of IL-1β, due
to its important role in both the innate and adaptive immune
response and in pathological mechanisms. It has been shown that
PRRSV could activate NLRP3 inflammasome in early stages of
infection but induce host’s immunosuppression later as measured
by determining the levels of pro-IL-1β and procaspase-1 mRNA
and the mature IL-1β protein in porcine alveolar macrophages
(PAM) (54). It is not surprising that nsp11 also interacts with
the RNA-silencing complex (RISC), as it has been demonstrated
in vitro in a MARC-145 cell line that this protein and nsp1α are
responsible for inhibiting RISC and downregulating argonaute-
2 protein expression increasing viral titter significantly, which
demonstrates a direct relationship between this silencing
complex and viral replication at least in vitro (55).
Other non-structural proteins have been studied but there
is an important gap on information about in vivo and in vitro
functions and interaction in signaling pathways. Additionally,
the enormous variation among strains makes it difficult to
characterize all protein variants and interactions with cell
systems (macrophages, Dendritic cells “DCs,” monocytes and
others) (Box 1).
Recently, a body of evidence associates host genetics with
different outcomes following PRRSV infection in the respiratory
and reproductive form of the disease (56–60). Although pathways
and mechanisms involved in specific disease-resistance traits
have not yet been fully characterized, it is clear that the genetic
variation in disease resilience is polygenic, regulating aspects
of both innate resistance and acquired immunity (56). In
connection with innate response, the average daily gain (ADG)
after PRRSV infection was associated with a single genomic
region in chromosome 4 (SSC4) which is best represented by
the SNP tag marker WUR, located in the 3′ non-coding region
of the interferon-inducible guanylate-binding protein 1 (GBP1)
gene (61). The pig genetic resistance to PRRSV infection has been
historically overlooked in PRRSV research probably generating
a confounding factor in immune response studies. A key gap
in the knowledge of PRRSV is linked the pig genetic variability
after PRRSV infection with the enormous variability of the virus
itself (Box 1).
In pigs, PRRSV replicates in cells belonging to the innate
immune system. PAMs are the primary cells to be infected in
the lungs as well as other cells of the monocyte/macrophage
lineage, which later could disseminate the virus to other
tissues or support replication to release viral particles into the
bloodstream (17) (Figure 2). Moreover, PRRSV is thought to
be able to infect professional antigen presenting cells such as
DCs and monocyte derived dendritic cells, (MoDC) impairing
their normal antigen presentation ability by inducing apoptosis,
down-regulating the expression of IFN-α, MHC class I, MHC
class II, CD11b/c and CD14, upregulating the expression of
IL-10 and inducing minimal Th1 cytokine secretion (62–65).
Nevertheless, new evidence suggest by in vivo and in vitro
experiments that specifically lung cDC1, cDC2, and MoDCs
are not infected by PRRSV-1 viruses from subtypes 1 and
3 and one possible explanation is the lower expression of
CD163 and CD169 in those 3 DC subtypes, associating previous
results of infection in DCs to culture conditions of monocytes
in vitro that could cause a sensibilization to infection by
certain strains as Lena (66). In addition, these findings were
also tested in tonsil cDC and tracheal cDC1 and cDC2
observing that those cell populations are not infected by PRRSV
virus (67, 68).
Moreover, a new type of PAM has been characterized
and named porcine intravascular macrophages (PIM) due
to its association to endothelial lung capillaries and not to
the alveoli, presenting strong capacity to phagocytised blood-
related particles (69). Importantly, when infected PIM cells
gave similar results of viral load to those derived from
infected PAM, but significantly upregulates of TNFα and
non-significantly IL-6 and IL-8 expression after infection
when compared to normal alveolar macrophages, indicating
that these cells have an important pro-inflammatory role
during PRRSV infection in the lungs (69). New interactions
between cells and the virus need to be further explored to
unravel possible immunological features that leads to correlates
of protection.
Recently, it has been shown that a domain within Nsp1α
is able to stimulate the secretion of CD83, which in turn
inhibits MoDC function in vitro, impairing the ability of MoDC
to stimulate T cell proliferation (70). Production of IFN α/β
and the mechanisms for cell activation by pDC are severely
suppressed during PRRSV infection, although these cells are
not permissive to PRRSV infection (71, 72). However, this
phenomenon is strain dependent, as other PRRSV strains are
able to stimulate pDC for IFN α/β production in large quantities
(73). Again, there is an enormous variability between PRRSV
strains in relation with their effect on antigen presenting cells
which prevent scientists from finding common mechanisms.
It might be of interest to link this key gap of knowledge
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for PRRSV with host genetics (Box 1). Moreover, in PRRSV-
infected cells, N is abundantly expressed benefiting from the
discontinuous transcription mechanism (74). This protein is also
distributed in the nucleus, induced by two nuclear localization
signals called cryptic NLS or NLS-1 and functional NLS or
NLS-2 (positions 10–13 and 41–47, respectively) (75). The
effect of N protein has been examined in PAMs and MoDCs
using transfection, finding a significant upregulation of IL-10
gene expression.
Natural killer (NK) cells constitute another powerful arm of
the innate immune system against PRRSV, particularly when
considering the high percentage of circulating NK cells in pigs
(76). The cytotoxic function of NK cells is reduced in PRRSV
infected pigs from day 2 after infection up to 3–4 weeks (38, 77,
78). Initial studies using in vitro systems demonstrated that the
stimulation of porcine NK cells with proinflammatory cytokines
(IL-2 and IL-15) was capable of activating NK cells and inducing
them to express high levels of IFN-γ and perforins to cause
lysis of infected cells, but a different scenario appears if cells are
evaluated post-infection, indicating that a virus such as PRRSV is
capable of impairing NK cell cytotoxicity (79). In vitro, the NK
cytotoxicity against PRRSV-infected PAMs was decreased and
degranulation of NK cells inhibited (80). In vivo, the immune
response is the same as that observed in vitro, with some
studies reporting that approximately half of viremic pigs had a
reduction >50% in NK cell-mediated cytotoxicity and enhanced
secretion of IL-4, IL-12, and IL-10 and reduced frequency
of cytotoxic T-cells (CD4−CD8+ T) and double positive T
cells (CD4+CD8+ T) and upregulated frequency regulatory
T- cells (Tregs) (81).
Acquired Immune Responses
Innate immune responses against PRRSV are obstructed by
different mechanisms as are adaptive responses. The modest
and delayed B cell mediated neutralizing antibody response is
one of the main characteristics associated to PRRSV acquired
immune responses. Even though PRRSV specific antibodies
appear early at 7–9 days post-infection, the efficacy of those
antibodies remains unclear. Neutralizing antibodies take longer,
appearing nearly 1 month after infection (34). However,
passive transfer of these neutralizing antibodies conferred
almost full protection in a PRRSV reproductive model (95%
of offspring alive after challenging pregnant sows with high
neutralizing antibody titter). Nevertheless, in another experiment
using the reproductive model, when the presence of PRRSV
was examined after the transfer of neutralizing antibodies,
lungs, tonsils, buffy coat cells, and peripheral lymph nodes
contained replicating PRRSV similar to infected controls,
although pigs were apparently protected against infection. In
summary, passive transfer of high neutralizing antibody titter
conferred protection to gilts and offspring (not detectable
viremia), but did not eliminate the presence of viral particles
in peripheral tissues nor transmission to animals they were
in contact with (82–84). Curiously, the role of neutralizing
antibodies in the protection against the respiratory form of
the disease is a key gap of knowledge for PRRSV. This
point is critical to define precisely targets for improved
vaccines based on the humoral immune response against this
virus (Box 1).
N protein is involved in several mechanisms for immune
evasion and is also one of the most immunogenic structural
proteins (75). Antibodies against N appear early during acute
infection, together with those against M and GP5 proteins,
but are non-neutralizing and could be involved in antibody
dependent enhancement (85, 86).
There are other “antibody-related mechanisms” that do not
necessarily involve neutralizing activity. Antibody-dependent
cell-mediated cytotoxicity (ADCC), antibody-dependent
complement-mediated cytotoxicity (CDC) and antibody-
dependent complement mediated virolysis (ADCV) have been
examined in the context of PRRSV, although none of these
mechanisms were evident during infection or have not been
deeply investigated on in vitro and in vivo models of this
virus (87). It is important to note that neutralizing antibodies
appear late in PRRSV infection and other immune mechanisms
(cellular or antibody mediated immune response) might be
acting to suppress viral replication in blood, causing the virus
to be isolated in lymphoid tissues and maintaining suboptimal
replication that will finally end in viral clearance. For type
PRRSV-2 it has been demonstrated that immunization of pigs
with ectodomain peptides from GP5/M complex did not induce
neutralizing antibodies (88) although those ectodomain-specific
antibodies generated were capable of binding virus.
An important feature that makes difficult to validate the
location of neutralizing epitopes is the number of glycosylations
in or around it. For PRRSV-1 strains, up to 3 glycosylations
may be found in, or flanking the GP5 neutralizing epitope
that is located between amino acids 37–45 (89), whereas for
PRRSV-2 strains there are four potential glycosylation sites (90).
When tested, PRRSV with mutations in GP5 glycosylation sites
(either at N44 or in the hypervariable region, upstream the
neutralizing epitope) enhanced immunogenicity with increased
concentration of antibodies directed to this epitope 5–10 fold
higher compared with those induced by the wild type strains
(89). Same results were obtained when administering another
deglycosylation mutant (double deglycosylation in the putative
glycosylation moieties on GP5) twice, which conferred better
protection against homologous challenge (91). In addition, when
this protein is expressed early during infection, it stimulates
production of early neutralizing antibodies and IFN-β, two
main antiviral mechanisms, demonstrating its role in induction
of self-protection mechanisms from the host (92). Available
data about neutralizing antibodies induced by this protein are
controversial, which may be due to the high variation among
PRRSV strains (93) and, as previously commented, the host
genetics. ORF5 is also complemented by a small frameshift
of the subgenomic mRNA called ORF5a, encoding a type I
membrane protein consisting primarily of alpha helix with a
membrane-spanning domain (called GP5a) that is incorporated
into virions as a very minor component, playing a role in viral
replication, as mutation in the initiation codon or premature
termination related to expression for this protein leads to
non-efficient viral replication and lower titter (94, 95). This
protein is capable of eliciting specific antibody immune response
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in natural infections and after immunizations, although those
are not neutralizing neither protective in a challenge trial
after infection, making difficult to define the role of this
particular small protein in the whole immune response and
viral clearance of PRRSV infection (96). In summary, the role
of humoral immunity remains elusive in PRRSV infection
(neutralizing and non-neutralizing antibodies) and a better
characterization will be required to overcome this relevant gap of
knowledge (Box 1).
Treg typically increase in number in chronic viral diseases
to prevent a persistent inflammatory response and pathological
damage associated to viral infections. Conversely, Tregs are
described as key contributors in modulating the host immune
response to viral infection. This cell population is an important
component in regulating the magnitude of the immune response
to infection (in viruses such as HIV and HCV), thus preventing
excessive inflammation and tissue damage. However, they can
also be inappropriately induced by viruses to switch the balance
of the immune response in favor of maintaining viral replication
(97). In PRRSV, the role of Tregs remains unclear and appears to
be a consequence of IL-10 induction of some strains as early as
2 days post infection (81). In some experiments, in vitro infected
DCs with PRRSV-1 exhibited an unbalanced ability to stimulate
T cell immune responses in a strain-dependent manner, but no
Tregs were detected, at least in vitro, as measured by expression of
CD25 and FoxP3markers (98). When using PRRSV-2 strains, the
case seems to be different, as the virus was capable of stimulating
IL-10 production with concomitant generation of Tregs (99)
which was associated to nucleocapsid protein expression in the
in vitro system. This group also suggested that IL-10 production
and Treg could be related to impaired gamma interferon (IFN-γ)
production and altered development of protective T-cell response
by inhibiting T-cell proliferation as seen in the early stage of
infection with viruses such as HCV. Vaccine strains currently in
use in the United States do not provide adequate heterologous
protection, one possible explanation could lay on their inability
to induce an adequate IFN-γ response due to their ability to
stimulate Tregs, at least in vitro (100). Structural conformation,
but not nuclear localization, of the expressed N protein was
suggested as essential for the ability to induce IL-10 that, in
consequence, causes induction of Tregs as measured by markers
CD4+CD25+Foxp3+ (99). It should be noted that when the role
of the nuclear localization signal was evaluated using deletion
mutants, results suggested that NLS-2 was not essential for
virus survival, although pigs developed a significantly shorter
duration of viremia and higher neutralizing antibodies than
those of wild-type PRRSV-infected pigs (101). The role of
Tregs cells in the immune response against PRRSV is a key
gap of knowledge in order to develop more efficacious PRRSV
vaccines (Box 1).
Moreover, reports have highlighted the impact of PRRSV
infection on thymic cellularity mainly as a loss of CD4+/CD8+
cells in the thymus of PRRSV-infected pigs. Acute lymphopenia,
thymic atrophy, and lymphadenopathy associated with the
presence of PRRSV antigen in the thymus are some of the
mechanisms whereby PRRSV suppresses the immune response.
In addition, presence of PRRSV antigens in the thymus could also
induce tolerance and presents a mechanism that could explain
the presence of Tregs during PRRSV infection (93). Nevertheless,
the picture is not complete and basic knowledge about the
effect of PRRSV on cell development in the thymus would
be of great interest to understand the effect of this viruses in
the host.
PRRSV immunology thus remains an unsolved puzzle due
to complex interactions between different viral strains and the
host. Similar immune responses could be the key feature of this
virus, such as persistence viremia, a strong inhibition of innate
cytokines (IFN-α/β, TNF-α, IL-1β, IFN-γ), dysregulation of NK
cell function (cytotoxicity and degranulation), rapid induction of
non-neutralizing antibodies, delayed appearance of neutralizing
antibody, late and low CD8+ T-cell response, and induction
of regulatory T cells (Tregs) (102). As a whole, neutralizing
antibodies and PRRSV-specific IFN-γ secreting cells do not
fully depict the immune effector functions related to protective
immunity, as the viral targets related to them are unknown. As
a consequence, correlates of protection remain elusive for this
infection due to the laborious work in vitro and in vivo and the
enormous genetic diversity that causes confusion and makes it
difficult to predict how immune responses against one isolate or
strain could be applied to another in a cross-protective immune
prediction model (103, 104). Without any doubt, the most
important gap of knowledge for PRRSV is the lack of correlates
of protection thatmakes extremely difficult to have robustmodels
to check vaccines efficacy against this disease (Box 1).
Vaccination Strategies in PRRSV. Classical
and Novel Vaccines
Since the beginning of PRRSV outbreaks in Europe and the
USA, the development of efficacious PRRSV vaccines has been
a challenge. Classical approaches are not working properly for
several reasons: viral mutation can lead to more pathogenic
strains, there is a lack of knowledge on how the porcine
immune system interacts with all PRRSV proteins, and most
importantly, there is no robust parameter (surrogatemarker) that
can be unequivocally linked with viral clearance. Thus, there is
no relationship between complete homologous or heterologous
protection and classic immunological parameters such as an
increase/decrease in particular cell population (105), IFN-
γ production, neutralizing antibodies (106), non-neutralizing
antibodies and clinical outcome (107). In addition, highly
divergent strains make it more difficult to develop a universal
vaccine for this virus (28).
Several different vaccines against PRRSV have reached the
market and have been reviewed recently (108). Most of these
vaccines rely upon modified live virus (Porcilis PRRS from
Merck, Ingelvac PRRSFLEX EU from Boehringer Ingelheim,
Amervac-PRRS from Hypra, Pyrsvac-183 from Syva) against
PRRSV-1, as well as some to control PRRSV-2 (Fostera PRRS
from Zoetis, Ingelvac PRRS MLV/Ingelvac PRRSATP from
Boehringer Ingelheim). There is also evidence that most MLV
vaccines of both PRRSV-1 and PRRSV-2 species elicit specific
humoral and cell-mediated immune (CMI) responses, as they
confer protection to homologous parental strains and partial
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protection to heterologous strains. Although it is possible to
control some PRRSV outbreaks by use of MLV in combination
with good practices, there are major safety issues such as
a high mutation rate leading to reversion to virulence and
recombination among vaccine and wild type strains. Cases have
been reported in which new viruses have been introduced as a
consequence of MLV vaccines. For example, nucleotide sequence
identities of atypical Danish isolates were between 99.2 and 99.5%
with the vaccine virus RespPRRS and 99.0–99.3% with VR2332,
which is the parental virus to the vaccine virus, supporting
the conclusion that the introduction of PRRSV-2 in Denmark
was due to the spread of vaccine virus (109). In China a
recombination event was reported in which a PRRSV variant
with nucleotide deletions and insertions in the non-structural
protein 2 (nsp2) gene also showed a possible recombination
event between a MLV strain and a prototype Chinese
field strain (110).
Current inactivated vaccine approaches are not highly
effective since elicited immune responses are not enough to
prevent spreading of the virus. However, this type of vaccine
can augment anamnestic virus neutralizing antibodies and virus-
specific IFN-γ responses following a wild-type virus infection or
PRRSV-MLV vaccination which can contribute to viral clearance
(111, 112). Thus, the combination of modified live vaccines with
inactivated ones can be a reasonable approach to control the
disease under field conditions (113) but unfortunately, there
is no robust data comparing this approach with other options
available on the market. On the other hand, most inactivated
vaccines are not approved for use in the United States due to
the poor efficacy showed in challenge trials (114) as measured by
production of PRRSV specific neutralizing and non-neutralizing
antibodies and low cellular immune responses leading to their
failure in the porcine market. According to the Centre for
Food Security and Public Health of Iowa State University, only
BOX 2 | Exosomes and therapeutic applications in PRRSV.
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“BIOSUIS PRRS Inact EU+Am” is approved to be used in the US.
However, new strategies are being evaluated to overcome these
problems (115), including nanoparticle entrapped antigens (116–
119), plant based approaches (120) or vectored vaccines (121).
Several attempts have been made to use structural proteins to
develop vaccines against PRRSV because they are specific targets
of neutralizing antibodies. For this reason, one may hypothesize
that antibodies against those proteins could be the main key to
inhibit viral replication and spread as it is common for many
viruses. Approaches such as VLPs combining different structural
proteins have been tested (122–124), finding that anamnestic
response is possible (boosted IgG and IFN-γ producing cells)
in previously vaccinated or infected pigs but not in the pre-
challenge period. These structural proteins are able to prime
the immune system, but no reduction of viremia was observed
after challenge (123). Those results suggest that other viral
proteins may be targeted to induce a protective response in
pigs. A plausible explanation for this finding may be based on
the presence of few neutralizing epitopes in their sequences,
most of which are located in variable regions of the proteins,
to the phenomena of glycan shielding for epitopes and to the
high variability observed between PRRSV virus strains. Again, a
critical gap of knowledge for PRRSV is to precisely characterize
common epitopes that are present in all PRRSV strains. Epitopes
responsible for generating an efficient immune response eliciting
cross-protective immunity remained elusive. Taken together, this
evidence points to the need for new vaccination approaches
that comply with a pathogen free strategy, capable of eliciting
effective cellular and antibody responses with mid to long
term protection against homologous strains and preferable to
heterologous challenge as well.
Extracellular Vesicles As a New
Vaccination Approach
Extracellular vesicles(EVs) are gaining increased scientific
attention as novel vaccines against infectious diseases, including
animal diseases of veterinary importance by its capacity of
self-antigen presentation, activation of host cell and antibody
immune responses and more important, to induce protection in
lethal challenge trials (125–131) (Box 2). In the case of PRRSV,
artificial microRNAs (amiRNA) were initially synthetized to
try suppressing expression of sialoadhesin (Sn) or CD163 by
recombinant adenoviral vectors to be contained in exosomes,
causing a subexpression of Sn and CD163 at mRNA and
protein level, and reducing viral titter when porcine macrophages
were pre-treated with amiRNA thus providing new evidence
supporting the hypothesis that EVs can also serve as an efficient
small RNA transfer vehicle for pig cells (132). More recently,
PRRSV viral proteins associated to extracellular vesicles (EVs)
in the size range of exosomes, were reported (129). Moreover,
a targeted-pig trial using EVs from sera of infected pigs who
had overcome the disease, demonstrated that EVs are capable
of inducing specific IFN-γ secreting cells after a prime-boost
strategy, are safe, free-of-virus and can differentiate infected
from vaccinated animals (133), moreover, it was demonstrated
that those EVs contained antigenic viral proteins recognized
by pig immune sera and not by the pre-immune one. Of
interest, however, a recent article indicated that PRRSV derived
EVs are capable of transmitting the virus from one cell to
another (134). Whether these discrepancies are due to in vivo
vs. in vitro experimental work and methods applied to isolate
EVs from serum samples or culture supernatant, remains to
be determined.
EVs have also been explored as novel control strategies in
other viral diseases. For example, in respiratory syncytial virus
infection, EVs are released with a selected modified cargo when
compared with uninfected epithelial cells. When analyzed in
detail, several viral proteins and diverse species of RNA were
detected and capable of activating innate immune responses
through induction of cytokine and chemokine release (135).
Similar scenarios of viral proteins exported in EVs have been
observed and extensively reviewed for HIV/HCV/HTLV-1 (136),
EBV (137), and other viral diseases. Moreover, viral products
of various origin and size including Ebola Virus VP24, VP40,
and NP, Influenza Virus NP, Crimean-Congo Haemorrhagic
Fever NP, West Nile Virus NS3, and Hepatitis C Virus NS3,
when fused with Nef C-terminal domain through DNA vectors,
were directed to the EVs membrane or packaged into them
and remained stable after fusion. More importantly, when
injected in mice, DNA vectors expressing the diverse fusion
products elicited a well detectable antigen- specific CD8+ T
cell response associating with a cytotoxic activity potent enough
to kill peptide-loaded and/or antigen-expressing syngeneic cells,
proving its promising results as a cytotoxic T lymphocyte
vaccine (138).
Concluding Remarks
PRRSV is a complex disease and several gaps in the knowledge
of its economic impact, biology and evolution, genetic
polymorphism, mechanism of viral infections, elicitation of
protective immune responses and novel control strategies, have
been reviewed here (Box 1). Since the late 1980’s, different
approaches have permitted to examine more closely this virus
allowing the discovery of new features of the complex replication
cycle, the identification of proteins and nucleic acids playing
a role together with extracellular vesicles and nanotubules
in facilitating spreading, and a better understanding of
immune evasion (non-neutralizing antibodies, glycan shielding,
mutation, recombination events, among others) to further
vaccine development. Presently available PRRSV vaccines have
many limitations in terms of heterologous protection, but some
efforts have been made by combining new adjuvant formulations
with modified live viruses, DNA and peptide vaccines, as well as
extracellular vesicles a new vaccination approach. Advancing in
all these gaps in knowledge, will eventually accelerate eliminating
and eventually eradicating this devastating veterinary disease of
such huge economic importance.
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